Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Phio Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Phio Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Phio Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
Phio Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Phio Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Phio Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Phio Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Phio Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Phio Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Phio Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Gerrit Dispersyn, Dr. Med. Sc, serves as a Chief Executive Officer at Phio Pharmaceuticals Corp. (formerly knowns as at RXi Pharmaceuticals Corporation) since March 1, 2019. Dr. Dispersyn has been President of RXi Pharmaceuticals Corporation since November 14, 2018 and served as a Chief Operating Officer since November 14, 2018 until March 1, 2019. Dr. Dispersyn served as Chief Development Officer at RXi Pharmaceuticals Corporation from April 2017 to November 14, 2018. Dr. Dispersyn is the founder of Ingress, LLC, and a consultancy company providing R&D and clinical operations support to start-up companies, supporting several pharmaceutical drug development programs. Dr. Dispersyn is an accomplished leader in clinical, product and business development. He served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporation from 2014 to April 2017. In this role, he was responsible for Integra’s global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integra’s Senior Management Leadership team and several of the company’s core teams for M&A projects. Dr. Dispersyn has also been involved in Integra’s research and business activities related to Human Cells, Tissues and Cellular and Tissue based Products (HCT/Ps), an experience that could be beneficial for RXi’s newly added focus on immuno-oncology and cell therapy. Prior to that role, he served as the Vice President, Product Development & Portfolio Management for Barrier Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Dr. Dispersyn holds a Dr. Med. Sc. (Ph.D. in Medical Sciences), from the Faculty of Medicine, Maastricht University, Maastricht, the Netherlands, a post-graduate degree in Biomedical Imaging and a M.Sc. in Biochemistry, both from the University of Antwerp, Belgium.
Gerrit's compensation has increased whilst company is loss making.
Gerrit's remuneration is higher than average for companies of similar size in Germany.
President & CEO
VP of Finance & Administration and Secretary
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Phio Pharmaceuticals board of directors is about average.
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company’s lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.